SCHEMBL168796

SCHEMBL168796

CCCCCOC(=O)c1c2ccccc2nc2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.58
CYP3A4 P08684 2/20 0.58
MAPK1 P28482 2/20 0.58
TP53 P04637 2/20 0.58
ALDH1A1 P00352 5/20 0.56
LMNA P02545 4/20 0.56
KDM4E B2RXH2 4/20 0.52
GAA P10253 2/20 0.52
MAPT P10636 2/20 0.52
NSD2 O96028 1/20 0.52
CYP1A2 P05177 1/20 0.52
GLA P06280 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
HPGD P15428 1/20 0.52
CYP2C19 P33261 1/20 0.52
TDP1 Q9NUW8 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
ITGB1 P05556 1/20 0.51
ITGA4 P13612 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17961055 0.82 TSHR (0.51) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL3409345 0.82 TDP1 (0.44) CYP3A4ALDH1A1LMNAKDM4EGAA
Ammonia Solution, Strong SCHEMBL15940166 0.81 TSHR (0.59) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL8598930 0.81 ALDH1A1 (0.47) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL8596810 0.81 ALDH1A1 (0.47) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL9424810 0.80 MEN1 (0.45) ALDH1A1LMNAKDM4EMAPTGLA
SCHEMBL14990402 0.80 ALDH1A1 (0.61) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL31310821 0.80 ALDH1A1 (0.61) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL10387044 0.79 TSHR (0.57) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL434453 0.79 TSHR (0.51) TSHRCYP3A4MAPK1TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 554 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10641768-B2 Methods and kits for decreasing interferences from leukocytes in specific binding assays ABBOTT JAPAN CO. LTD. (JP) 2020-05-05 US claimed
US-20140072996-A1 METHODS AND KITS FOR DETECTING HEMOGLOBIN IN TEST SAMPLES ABBOTT LABORATORIES (US) 2014-03-13 US claimed
US-8574858-B2 Autoantibody enhanced immunoassays and kits ABBOTT LABORATORIES (US) 2013-11-05 US claimed
EP-2598534-A1 ANTIBODIES RELATING TO PIVKA-II AND USES THEREOF Abbott Laboratories (US) 2013-06-05 EP claimed
US-20130029353-A1 AUTOANTIBODY ENHANCED IMMUNOASSAYS AND KITS ABBOTT LABORATORIES (US) 2013-01-31 US claimed
WO-2013008900-A1 METHODS AND KITS FOR DECREASING INTERFERENCES FROM LEUKOCYTES IN SPECIFIC BINDING ASSAYS ABBOTT JAPAN CO. LTD. (JP) 2013-01-17 WO claimed
US-20130011826-A1 METHODS AND KITS FOR DECREASING INTERFERENCES FROM LEUKOCYTES IN SPECIFIC BINDING ASSAYS ABBOTT LABORATORIES (US) 2013-01-10 US claimed
US-8304201-B2 Autoantibody enhanced immunoassays and kits ABBOTT LABORATORIES (US) 2012-11-06 US claimed
US-20120270258-A1 METHODS AND KITS FOR DETECTING HEMOGLOBIN IN TEST SAMPLES ABBOTT LABORATORIES (US) 2012-10-25 US claimed
EP-2507626-A1 PEPTIDE REAGENTS AND METHOD FOR INHIBITING AUTOANTIBODY ANTIGEN BINDING Abbott Laboratories (US) 2012-10-10 EP claimed
US-20090286256-A1 ISOLATED HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES AND METHODS AND KITS FOR DETECTING HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES ABBOTT LABORATORIES (US) 2009-11-19 US claimed
US-20090286329-A1 ISOLATED HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES AND METHODS AND KITS FOR DETECTING HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES ABBOTT LABORATOIRES (US) 2009-11-19 US claimed
WO-2009131963-A2 METHOD AND KIT FOR ASSESSING THE SUITABILITY OF ERYTHROCYTES FOR TRANSFUSION ABBOTT LABORATORIES (US) 2009-10-29 WO claimed
US-20090263845-A1 METHOD AND KIT FOR ASSESSING THE SUITABILITY OF ERYTHROCYTES FOR TRANSFUSION ABBOTT LABORATORIES (US) 2009-10-22 US claimed
WO-2009085883-A1 THE ACCURACY OF MYELOPEROXIDASE ASSAYS AND THE DETECTION OF MYELOPEROXIDASE AUTOANTIBODIES ABBOTT LABORATORIES (US) 2009-07-09 WO claimed
US-20090162876-A1 MYELOPEROXIDASE ASSAYS ABBOTT LABORATORIES (US) 2009-06-25 US claimed
WO-2009076330-A1 STABILIZING COMPOSITIONS, METHODS AND KITS FOR CHEMILUMINESCENT ASSAYS ABBOTT LABORATORIES (US) 2009-06-18 WO claimed
US-20090148879-A1 Stabilizing Compositions, Methods and Kits for Chemiluminescent Assays ABBOTT LABORATORIES 2009-06-11 US claimed
WO-2008124749-A1 ACRIDINIUM PHENYL ESTERS USEFUL IN THE ANALYSIS OF BIOLOGICAL SAMPLES ABBOTT LABORATORIES (US) 2008-10-16 WO claimed
US-20080248493-A1 ACRIDINIUM PHENYL ESTERS USEFUL IN THE ANALYSIS OF BIOLOGICAL SAMPLES ABBOTT LABORATORIES 2008-10-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286329-A1 ISOLATED HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES AND METHODS AND KITS FOR DETECTING HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES NPPA, NPR1, NPR3 TSHR 180/4885CYP3A4 4880/4885MAPK1 3772/4885
US-20090286256-A1 ISOLATED HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES AND METHODS AND KITS FOR DETECTING HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES NPPA, NPR1, NPR3 TSHR 180/4885CYP3A4 4880/4885MAPK1 3772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.